Nora Hutchinson, Katarzyna Klas, Benjamin G. Carlisle, Jonathan Kimmelman, Marcin Waligora
{"title":"早期SARS-CoV-2治疗和预防试验的信息量有多大?在clinicaltrials.gov上注册的试验的纵向队列分析","authors":"Nora Hutchinson, Katarzyna Klas, Benjamin G. Carlisle, Jonathan Kimmelman, Marcin Waligora","doi":"10.1101/2021.08.25.21262155","DOIUrl":null,"url":null,"abstract":"<strong>Background</strong> Early in the SARS-CoV-2 pandemic, commentators warned that some COVID trials were inadequately conceived, designed and reported. Here, we retrospectively assess the prevalence of informative COVID trials launched in the first 6 months of the pandemic.","PeriodicalId":501154,"journal":{"name":"medRxiv - Medical Ethics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"How Informative Were Early SARS-CoV-2 Treatment and Prevention Trials? A longitudinal cohort analysis of trials registered on clinicaltrials.gov\",\"authors\":\"Nora Hutchinson, Katarzyna Klas, Benjamin G. Carlisle, Jonathan Kimmelman, Marcin Waligora\",\"doi\":\"10.1101/2021.08.25.21262155\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Background</strong> Early in the SARS-CoV-2 pandemic, commentators warned that some COVID trials were inadequately conceived, designed and reported. Here, we retrospectively assess the prevalence of informative COVID trials launched in the first 6 months of the pandemic.\",\"PeriodicalId\":501154,\"journal\":{\"name\":\"medRxiv - Medical Ethics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Medical Ethics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2021.08.25.21262155\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Medical Ethics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2021.08.25.21262155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
How Informative Were Early SARS-CoV-2 Treatment and Prevention Trials? A longitudinal cohort analysis of trials registered on clinicaltrials.gov
Background Early in the SARS-CoV-2 pandemic, commentators warned that some COVID trials were inadequately conceived, designed and reported. Here, we retrospectively assess the prevalence of informative COVID trials launched in the first 6 months of the pandemic.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
